Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.
Calcium levofolinate
FOLFIRI
Sodium levofolinate
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
30
12
2020
accepted:
12
03
2021
pubmed:
26
3
2021
medline:
29
9
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen. A comparison with calcium levofolinate (Ca-Lev) showed a similar toxicity profile. The advantages of Na-Lev over Ca-Lev might be the faster drug preparation and the shorter time of drug administration. The objectives of this study were to compare the safety profiles of sodium levofolinate (Na-Lev) and calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) in the FOLFIRI regimen and to measure the organizational impact of the introduction of Na-Lev on drug production and administration. The study opened in November 2015 and closed in August 2019. Patients with gastrointestinal cancers who were candidates for treatment with the FOLFIRI regimen were included in this nonrandomized study. Age ≥18 years, life expectancy >3 months, adequate bone marrow reserve, adequate hepatic and renal function, and an ECOG performance status of 0-2 were required. Patients in the Ca-Lev arm received a 2-hour infusion of Ca-Lev followed by 5-FU, whereas those in the Na-Lev arm received Na-Lev and 5-FU administered in a single 48-hour pump. Sixty patients were enrolled, 30 in each arm. Patient characteristics were balanced. Grade (G)1-2 adverse events occurred in 18 (60.0%) and 19 (63.4%) patients of Na-Lev and Ca-Lev cohorts, respectively, whereas G3-4 adverse events occurred in 12 (40.0%) and 11 (36.6%) patients, respectively. The use of Na-Lev enabled us to save approximately 13 minutes for drug preparation and 2 hours for treatment administration, per patient per cycle. Na-Lev showed a reassuring toxicity profile and a favorable impact on drug preparation and administration.
Sections du résumé
LESSONS LEARNED
The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen. A comparison with calcium levofolinate (Ca-Lev) showed a similar toxicity profile. The advantages of Na-Lev over Ca-Lev might be the faster drug preparation and the shorter time of drug administration.
BACKGROUND
The objectives of this study were to compare the safety profiles of sodium levofolinate (Na-Lev) and calcium levofolinate (Ca-Lev) in combination with 5-fluorouracil (5-FU) in the FOLFIRI regimen and to measure the organizational impact of the introduction of Na-Lev on drug production and administration.
METHODS
The study opened in November 2015 and closed in August 2019. Patients with gastrointestinal cancers who were candidates for treatment with the FOLFIRI regimen were included in this nonrandomized study. Age ≥18 years, life expectancy >3 months, adequate bone marrow reserve, adequate hepatic and renal function, and an ECOG performance status of 0-2 were required. Patients in the Ca-Lev arm received a 2-hour infusion of Ca-Lev followed by 5-FU, whereas those in the Na-Lev arm received Na-Lev and 5-FU administered in a single 48-hour pump.
RESULTS
Sixty patients were enrolled, 30 in each arm. Patient characteristics were balanced. Grade (G)1-2 adverse events occurred in 18 (60.0%) and 19 (63.4%) patients of Na-Lev and Ca-Lev cohorts, respectively, whereas G3-4 adverse events occurred in 12 (40.0%) and 11 (36.6%) patients, respectively. The use of Na-Lev enabled us to save approximately 13 minutes for drug preparation and 2 hours for treatment administration, per patient per cycle.
CONCLUSION
Na-Lev showed a reassuring toxicity profile and a favorable impact on drug preparation and administration.
Identifiants
pubmed: 33764600
doi: 10.1002/onco.13762
pmc: PMC8342582
doi:
Substances chimiques
Sodium
9NEZ333N27
Leucovorin
Q573I9DVLP
Calcium
SY7Q814VUP
Fluorouracil
U3P01618RT
Camptothecin
XT3Z54Z28A
Banques de données
ClinicalTrials.gov
['NCT04680104']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1314-e1319Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Anticancer Res. 2014 Dec;34(12):7233-8
pubmed: 25503154
J Clin Oncol. 1991 Apr;9(4):625-30
pubmed: 2066758
Ann Oncol. 2011 Jun;22(6):1358-1366
pubmed: 21119032
Anticancer Drugs. 2009 Mar;20(3):165-73
pubmed: 19125117
Eur J Cancer. 1995 Sep;31A(10):1717
pubmed: 7488434
BMC Cancer. 2016 Aug 31;16:699
pubmed: 27582078
Br J Cancer. 2004 May 17;90(10):1893-7
pubmed: 15138468
Oncol Res. 2017 Aug 7;25(7):1129-1140
pubmed: 28109077
Med Sci Monit. 2011 May;17(5):CR248-58
pubmed: 21525806
Oncology. 1998 Jul-Aug;55(4):320-5
pubmed: 9663421
Anticancer Drugs. 2005 Apr;16(4):435-40
pubmed: 15746580
Anticancer Res. 2017 Jul;37(7):3771-3779
pubmed: 28668873
Acta Gastroenterol Belg. 2012 Mar;75(1):14-21
pubmed: 22567742
Onkologie. 2004 Oct;27(5):449-54
pubmed: 15585974
J Clin Oncol. 1989 Apr;7(4):425-32
pubmed: 2926468